Stay updated on Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial

Sign up to get notified when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added; the lapse-in-government-funding notice was removed; no changes to trial content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T11:52:12.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding delays and updated the page revision to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T06:26:41.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Added a 'Show glossary' toggle and updated labels and revision information (capitalization changes for QC-related fields; Revision: v3.4.0, replacing v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T06:13:10.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Core study details such as eligibility criteria, outcomes, and treatment arms remain unchanged. The observed differences are minor formatting and wording edits.
    Difference
    0.1%
    Check dated 2026-01-21T03:46:48.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    Revision: v3.3.4 replaces v3.3.3; this appears to be a small metadata/UI update and does not affect study content.
    Difference
    0.2%
    Check dated 2026-01-14T01:39:36.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Added Revision: v3.3.3 to the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.2%
    Check dated 2025-12-23T08:37:39.000Z thumbnail image

Stay in the know with updates to Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.